REZDIFFRAREZDIFFRAREZDIFFRA

The FDA accepted REZDIFFRA depending on proof of efficacy from the clinical demo, Demo 1, of 888 individuals who experienced a liver biopsy exhibiting inflammation on account of NASH with average or Superior liver scarring, but not with cirrhosis from the liver.Abbreviations: AUCtau,ss = spot under the concentration-versus-time curve above one part